Announcements Trials

Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Breast 10 Lymphoid 3 Thoracic 2 Gynecologic 2 Sarcoma 1 Plasma cell 1 Other hematologic neoplasm 1 Other 1 Myeloid 1 Genitourinary 1 Dermatologic 1 CNS 1

Conditions

Melanoma 1 Cardiotoxicity 1

Interventions

Nivolumab 168 Ipilimumab 152 pembrolizumab 143 Cyclophosphamide 126 Interleukin-2 70 aldesleukin 69 fludarabine phosphate 68 Radiotherapy 67 Biopsy 53 Temozolomide 48 Blood Specimen Collection 45 Peripheral Blood Stem Cell Transplantation 44 fludarabine 43 Radiosurgery 40 trametinib 38 Vemurafenib 36 dabrafenib 33 sargramostim 32 Bevacizumab 31 Aminolevulinic Acid 31 Magnetic Resonance Spectroscopy 30 Mycophenolic Acid 29 Specimen Handling 28 Whole-Body Irradiation 27 Photochemotherapy 26 Imiquimod 26 CTLA-4 Antigen 26 Busulfan 26 Tacrolimus 25 Surveys and Questionnaires 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Echocardiography × Dermatologic × Clear all

NCT06605833 2025-10-01

CARD-IO

Royal Marsden NHS Foundation Trust

Enrolling by invitation

Melanoma, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡